Antipsychotic use among nursing home residents

JAMA

Volumn 309, Issue 5, 2013, Pages 440-442

  Briesacher, Becky A ^a   Tjia, Jennifer ^a   Field, Terry ^a   Peterson, Daniel ^a   Gurwitz, Jerry H ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

DRUG USE; GEOGRAPHIC DISTRIBUTION; HUMAN; LENGTH OF STAY; LETTER; LONG TERM CARE; MAJOR CLINICAL STUDY; NURSING HOME PATIENT; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT DURATION;

EID: 84873252239     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.211266     Document Type: Letter

References (5)

1. Briesacher BA, Limcangco MR, Simoni-Wastila L, et al. The quality of antipsychotic drug prescribing in nursing homes. Arch Intern Med. 2005;165(11):1280-1285.
2. Maher AR, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA. 2011;306(12):1359-1369.
3. Chen Y, Briesacher BA, Field TS, Tjia J, Lau DT, Gurwitz JH. Unexplained variation across US nursing homes in antipsychotic prescribing rates. Arch Intern Med. 2010;170(1):89-95.
4. Shorr RI, Fought RL, Ray WA. Changes in antipsychotic drug use in nursing homes during implementation of the OBRA-87 regulations. JAMA. 1994;271(5):358-362.
5. Rovner BW, Edelman BA, Cox MP, Shmuely Y. The impact of antipsychotic drug regulations on psychotropic prescribing practices in nursing homes. Am J Psychiatry. 1992;149(10):1390-1392.